Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub

Therapeutic Classification

antimetabolite Registry

Clinical reference for antimetabolite medications. Access safety monographs, dosing adjustments, and drug-drug interactions for all registered brand names and generics in this class.

Registered Medications (antimetabolite)

This therapeutic registry is dynamically synthesized from professional clinical sources. Listing of a medication does not imply equivalence; refer to individual monographs for head-to-head pharmacological data.

MedicationTherapeutic ClassMaternal Safety

ABITREXATE

Comprehensive clinical and safety monograph for ABITREXATE (ABITREXATE).

Antimetabolite

caution

ADRUCIL

Comprehensive clinical and safety monograph for ADRUCIL (ADRUCIL).

Antimetabolite

caution

CAPECITABINE

Warfarin interaction can lead to serious bleeding and death Patients with DPD deficiency are at risk for severe toxicity.

Antimetabolite

avoid

CYTARABINE

Comprehensive clinical and safety monograph for CYTARABINE (CYTARABINE).

Antineoplastic Antimetabolite

caution

CYTOSAR-U

Comprehensive clinical and safety monograph for CYTOSAR-U (CYTOSAR-U).

Antineoplastic Antimetabolite

caution

FLOXURIDINE

Comprehensive clinical and safety monograph for FLOXURIDINE (FLOXURIDINE).

Antineoplastic Antimetabolite

caution

FLUDARABINE PHOSPHATE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and neurotoxicity.

Antimetabolite

avoid

FLUOROURACIL

Leucovorin enhances the toxicity and efficacy Can cause severe myelosuppression and mucositis.

Antimetabolite

avoid

FUDR

Comprehensive clinical and safety monograph for FUDR (FUDR).

Antimetabolite (Antineoplastic)

caution

GEMCITABINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and hemolytic uremic syndrome.

Antimetabolite

avoid

GEMCITABINE HYDROCHLORIDE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and hemolytic uremic syndrome.

Antimetabolite

avoid

HYDROXYUREA

No significant drug interactions For topical use only can cause mild irritation.

Antimetabolite

safe

INFUGEM

Comprehensive clinical and safety monograph for INFUGEM (INFUGEM).

Antimetabolite Antineoplastic Agent

caution

MERCAPTOPURINE

Allopurinol inhibits xanthine oxidase increasing levels of active metabolites leading to severe myelosuppression Myelosuppression is dose-related and requires frequent CBC monitoring.

Antimetabolite

avoid

METHOTREXATE

NSAIDs and probenecid can decrease renal excretion and increase levels Can cause myelosuppression and hepatotoxicity.

Antimetabolite

avoid

METHOTREXATE LPF

NSAIDs and probenecid can decrease renal excretion and increase levels Can cause myelosuppression and hepatotoxicity.

Antimetabolite

avoid

METHOTREXATE PRESERVATIVE FREE

NSAIDs and probenecid can decrease renal excretion and increase levels Can cause myelosuppression and hepatotoxicity.

Antimetabolite

avoid

METHOTREXATE SODIUM

NSAIDs and probenecid can decrease renal excretion and increase levels Can cause myelosuppression and hepatotoxicity.

Antimetabolite

avoid

METHOTREXATE SODIUM PRESERVATIVE FREE

NSAIDs and probenecid can decrease renal excretion and increase levels Can cause myelosuppression and hepatotoxicity.

Antimetabolite

avoid

OTREXUP

Comprehensive clinical and safety monograph for OTREXUP (OTREXUP).

Antimetabolite (DMARD)

caution

OTREXUP PFS

Comprehensive clinical and safety monograph for OTREXUP PFS (OTREXUP PFS).

Antimetabolite

caution

PURIXAN

Comprehensive clinical and safety monograph for PURIXAN (PURIXAN).

Antimetabolite

caution

PYQUVI

Comprehensive clinical and safety monograph for PYQUVI (PYQUVI).

Antimetabolite

caution

RASUVO

Comprehensive clinical and safety monograph for RASUVO (RASUVO).

Antimetabolite

caution

REDITREX

Comprehensive clinical and safety monograph for REDITREX (REDITREX).

Antineoplastic Antimetabolite

caution

SIKLOS

Comprehensive clinical and safety monograph for SIKLOS (SIKLOS).

Antimetabolite

caution

THIOGUANINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and hepatotoxicity.

Antimetabolite

avoid

TREXALL

Comprehensive clinical and safety monograph for TREXALL (TREXALL).

Antimetabolite

caution

VERCYTE

Comprehensive clinical and safety monograph for VERCYTE (VERCYTE).

Antineoplastic Antimetabolite

caution

XATMEP

Comprehensive clinical and safety monograph for XATMEP (XATMEP).

Antimetabolite

caution

XELODA

Comprehensive clinical and safety monograph for XELODA (XELODA).

Antimetabolite

caution